Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
A Tier-1 Indian innovator pharma company running a DSIR-approved R&D innovation centre commissions clinical CROs for Phase 2 dose-finding and Phase 3 registration studies at aggregate outsourced fees of the order of Rs 60 crore per molecule programme. The Section 35(2AB) reconciliation surface is a per-CRO per-invoice carve-out between the clinical trial expenditure operating under contract linked to the DSIR-approved facility (with the trial protocol filed at DSIR) — which is eligible for the 100 percent weighted deduction — and the regulatory strategy consulting or market-access research portion of the same CRO umbrella, which is not scientific research within the meaning of Section 35(2AB) and drops to Section 37 general-deduction treatment. Each CRO invoice must be flagged for eligibility, matched to a TDS challan under Section 194J (India-domiciled CRO) or Section 195 (foreign CRO or foreign parent) at the applicable Finance Act or DTAA rate, retranslated under Ind AS 21 where the payable straddles a reporting date, and certified in Form 3CL by the DSIR-empanelled Chartered Accountant with the invoice-level supporting evidence chain intact.
Build a CRO contract register keyed to each contract with the Section 35(2AB) eligibility flag per scope-of-work line item, the DSIR facility linkage (Form 3CM approval reference), and the DSIR-filed protocol acknowledgement. Extract each CRO invoice with the scope-of-work line, the eligible-versus-non-eligible split, the invoice currency (INR for domestic CROs, USD or other for foreign CROs), the transaction-date spot rate for the rupee-equivalent expenditure feed, and the reporting-date closing rate for Ind AS 21 retranslation of any unsettled payable. Match each CRO invoice to the TDS challan — Section 194J code 1005 at 10 percent for India-domiciled CROs, Section 195 at the applicable DTAA rate for foreign CROs — with the CIN (challan identification number) as the reconciliation key. Feed the eligible-portion aggregate to the Form 3CL year-end certification and the eligible-versus-Section-37 split to the Form 3CLA return-of-income schedule. Hold the CRO payable ledger with the running forex-retranslation trail as a distinct control column so the transaction-date rupee value flowing into the Section 35(2AB) claim base is not conflated with the subsequent forex movement on the payable.
R&D facility master keyed to the DSIR Form 3CM approval reference (facility name, address, three-year renewal cycle, approved scope); CRO master keyed to each CRO's PAN and Section 194J code 1005 or non-resident status under Section 195 (with the applicable DTAA article and rate); CRO contract register keyed to contract reference with the scope-of-work line items, the Section 35(2AB) eligibility flag per line, the DSIR facility linkage, and the DSIR-filed protocol acknowledgement; CRO invoice register with invoice-level Section 35(2AB) eligibility flag, invoice currency, transaction-date spot rate, and reporting-date closing rate; TDS challan register matched invoice-by-invoice with CIN as the reconciliation key; Ind AS 21 forex retranslation working per foreign CRO payable straddling a reporting date; Form 3CL supporting-evidence file per invoice; Form 3CLA return-of-income schedule with the eligible-versus-Section-37 split; Section 40(a)(i) disallowance monitor for any foreign CRO invoice where the TDS challan is missing or late-deposited.
A year-end Section 35(2AB) CRO expenditure certification pack per DSIR-approved facility: the aggregate eligible outsourced CRO expenditure with per-CRO per-invoice detail, the Section 37 non-eligible carve-out with the regulatory strategy consulting and market-access research lines separately disclosed, the Form 3CL DSIR-empanelled Chartered Accountant certification with the invoice-level supporting-evidence chain intact, the Form 3CLA schedule feed for the ITR-6 filing, the TDS challan reconciliation showing every CRO invoice matched to a Section 194J or Section 195 deposit with the CIN reference, the Ind AS 21 forex retranslation trail for foreign CRO payables, and a Section 40(a)(i) exposure flag for any foreign CRO leg where the TDS chain is incomplete. The pack feeds the ITR-6 return and stands as the defence file at any subsequent Section 148 reopening or scrutiny under the assessment cycle.
A Tier-1 Indian innovator pharma company running a DSIR-approved R&D innovation centre closes its FY 2026-27 books with an outsourced Contract Research Organisation (CRO) spend line of the order of Rs 60 crore per active molecule programme — Phase 2 dose-finding at an India-domiciled clinical CRO, Phase 3 registration-study execution at the India arm of a global CRO, regulatory strategy consulting from a large international group, and bioanalytical work at a specialised bioequivalence CRO. The Section 35(2AB) claim carries a 100 percent weighted deduction on eligible revenue and capital expenditure incurred at the DSIR-approved facility. The reconciliation surface separating a defensible Form 3CL certification from a Section 148 reopening exposure is the per-CRO per-invoice carve-out between clinical trial expenditure operating under contract linked to the DSIR facility (eligible) and regulatory strategy consulting or market-access research (non-eligible for Section 35(2AB) but deductible under Section 37 wholly-and-exclusively). This is clinical trial CRO expenditure Section 35(2AB) eligibility pharma at operating scale, and the discipline is a CRO contract register keyed to each invoice’s eligibility flag, TDS challan match, forex retranslation trail, and Form 3CL supporting-evidence chain.
Quick reference
| Aspect | Detail |
|---|---|
| Governing provision | Section 35(2AB), Income-tax Act 2025 (successor to Income-tax Act 1961) |
| Weighted deduction rate | 100 percent from AY 2021-22 onwards (was 150 percent AY 2018-19 to AY 2020-21; 200 percent up to AY 2017-18) |
| Prescribed authority | Department of Scientific and Industrial Research (DSIR), Ministry of Science and Technology |
| Facility approval | Form 3CM (three-year renewal cycle) |
| Year-end quantum certification | Form 3CL by DSIR-empanelled Chartered Accountant, filed with return |
| Return-of-income schedule | Form 3CLA (ITR-6 schedule for companies) |
| Eligibility guidelines | DSIR/Sec35(2AB)/1/2021 |
| CRO eligibility test (three legs) | Contract linked to DSIR-approved facility; clinical trial protocol filed at DSIR under facility umbrella; expenditure certified in Form 3CL by DSIR-empanelled CA |
| Non-eligible categories | Land and buildings; civil engineering; market research; regulatory strategy consulting; testing outside DSIR-approved facility |
| Fallback deduction for non-eligible portion | Section 37 (wholly-and-exclusively for the purposes of business) |
| TDS on India-domiciled CRO | Section 194J at 10 percent (payment code 1005 in the standing payment-code schedule) |
| TDS on foreign CRO or foreign parent | Section 195 at the lower of Finance Act rate and applicable DTAA rate |
| Disallowance for TDS non-deduction on foreign CRO | Section 40(a)(i) — full disallowance of the foreign CRO fee in the year of payment |
| Forex treatment on foreign CRO payable | Ind AS 21 — retranslate at each reporting date closing spot; recognise exchange difference in P&L |
The reconciliation in one paragraph
An innovator pharma company running a DSIR-approved in-house R&D facility earns the Section 35(2AB) 100 percent weighted deduction on revenue and capital R&D expenditure (excluding land and buildings) incurred at the facility. Outsourced Contract Research Organisation (CRO) fees are eligible only where the CRO operates under a contract linked to the DSIR-approved facility, the clinical trial protocol is filed at DSIR under the facility umbrella, and the expenditure is certified in Form 3CL by the DSIR-empanelled Chartered Accountant at year-end (DSIR guidelines DSIR/Sec35(2AB)/1/2021). Clinical trial execution at a CRO passing the three-leg test is eligible; regulatory strategy consulting, market-access research and testing outside the DSIR facility are not — those legs drop to Section 37 general-deduction treatment without the weighted-deduction benefit. The TDS overlay: India-domiciled CROs fall under Section 194J at 10 percent (payment code 1005); foreign CROs and foreign parents fall under Section 195 at the applicable DTAA rate; failure to deduct on a foreign CRO invoice triggers Section 40(a)(i) full disallowance of the fee in the year of payment. Foreign CRO payables straddling a reporting date carry an Ind AS 21 retranslation surface — the Section 35(2AB) claim base is the transaction-date rupee value, not the reporting-date or settlement-date value.
What the scenario looks like in India
The Indian innovator R&D landscape is anchored by a handful of Tier-1 integrated formulators that run dedicated in-house R&D innovation centres with DSIR-approved facility status — Form 3CM in hand, scientific research staff numbering in the several hundred, and Form 3CL year-end certifications of eligible R&D expenditure that regularly cross Rs 500 crore per annum at the top of the range. Illustrative Tier-1 R&D-heavy players include Sun Pharmaceutical Industries (Sun Pharma Innovation Centre at Vadodara in Gujarat), Dr Reddy’s Laboratories (integrated discovery research at Bollaram in Telangana), Zydus Lifesciences (Zydus Cadila Research at Ahmedabad), Torrent Pharmaceuticals (New Chemical Entity R&D at Ahmedabad), Alkem Laboratories, Biocon Biologics, Ajanta Pharma, and Cipla. Tier-2 innovator programmes at Neuland Laboratories, Suven Life Sciences / Suven Pharma, Ipca Laboratories, Piramal Pharma, and Natco Pharma round out the DSIR-approved facility population.
The outsourced clinical trial CRO industry that these innovators commission is a mix of India-domiciled specialised CROs and India arms of global CROs. Safe illustrative CRO names in the standing operating landscape include Syngene International (the Biocon integrated research subsidiary, India-domiciled), IQVIA India, Parexel India, Icon Clinical (India operations), Lambda Therapeutic Research, and Veeda Clinical Research. Some CROs also carry CDMO / CRAMS capacity — the same entity may offer contract research, contract manufacturing and analytical services under a single umbrella — which complicates the Section 35(2AB) eligibility carve-out because only the scientific-research CRO fee portion is eligible; the contract manufacturing portion is not.
The reference persona for this reconciliation is a Tier-1 Indian innovator running a DSIR-approved R&D innovation centre at Vadodara in Gujarat, commissioning three CROs for the FY 2026-27 pipeline: an India-domiciled specialised CRO for Phase 2 dose-finding of an internally-discovered diabetes molecule (illustrative fee Rs 42 crore); the India arm of a global CRO for Phase 3 registration-study consulting on a separate cardiovascular molecule (illustrative fee Rs 18 crore, dominated by regulatory strategy rather than clinical trial execution); and a specialised bioequivalence CRO for standing bioanalytical work (illustrative FY 2026-27 fees Rs 6 crore). Aggregate outsourced CRO spend on the innovation centre sits of the order of Rs 60 to 70 crore across the three commissions.
The regulatory overlay — Section 35(2AB), DSIR facility approval, Form 3CL, and the CRO eligibility test
Section 35(2AB) of the Income-tax Act 2025 (successor to Section 35(2AB) of the 1961 Act) grants a 100 percent weighted deduction of revenue expenditure and capital expenditure (other than expenditure on land and buildings) incurred on scientific research at an in-house research and development facility approved by the prescribed authority. The weighted-rate history matters for closing-year comparatives — the rate was 200 percent up to assessment year 2017-18, 150 percent from AY 2018-19 to AY 2020-21, and stands at 100 percent from AY 2021-22 onwards. The prescribed authority is the Department of Scientific and Industrial Research (DSIR) under the Ministry of Science and Technology. DSIR approves the facility in Form 3CM on an initial three-year renewal cycle. A DSIR-empanelled Chartered Accountant certifies year-end eligible R&D expenditure in Form 3CL; the Return of Income (typically ITR-6) carries the claim in Form 3CLA with the Form 3CL quantum, the Form 3CM approval reference, and the revenue-versus-capital split.
DSIR guidelines DSIR/Sec35(2AB)/1/2021 set out the categories of eligible R&D expenditure: scientific research staff salaries; consumables (chemicals, biological materials, cell lines, reference standards); clinical trial internal costs (in-house preclinical work, Phase 1 bioanalytical work at the approved facility); patent filing and prosecution costs (Indian and foreign); cost of scientific publications; and equipment and other items on the DSIR-approved list. The guidelines expressly exclude: land and buildings; civil engineering; market research; regulatory strategy consulting; and testing outside the DSIR-approved facility.
For outsourced clinical trial fees paid to a Contract Research Organisation, DSIR/Sec35(2AB)/1/2021 sets out a three-leg eligibility test. First, the CRO must operate under a contract linked to the DSIR-approved facility (the contract references the Form 3CM approval and the facility name; the CRO’s deliverables feed the in-house research programme rather than a standalone third-party study). Second, the clinical trial protocol must be filed at DSIR under the facility umbrella (the trial is treated as an extension of the approved facility’s scientific research programme). Third, the expenditure must be certified in Form 3CL with invoice-level supporting evidence of the CRO’s activity mapping to the facility’s research programme. A CRO fee that fails any leg drops out of the Section 35(2AB) claim and lands in Section 37 general-deduction treatment — deductible as wholly-and-exclusively business expenditure but without the weighted-deduction benefit.
The TDS overlay adds the second reconciliation surface. Payments to an India-domiciled CRO fall under Section 194J of the Income-tax Act 2025 at 10 percent, reported under payment code 1005 in the standing payment-code schedule for fees for professional services. Payments to a foreign CRO or a foreign parent (invoicing directly from outside India, or via a group cost-recharge mechanism) fall under Section 195 at the rate specified in the Finance Act or the applicable Double Taxation Avoidance Agreement (DTAA), whichever is more beneficial. For a US-parent CRO the India-US DTAA Article 12 rate for fees for included services applies; for a UK-parent CRO the India-UK DTAA Article 13 rate applies. Failure to deduct TDS on a foreign CRO payment triggers Section 40(a)(i) disallowance — the full expenditure is disallowed in the year of payment, and the Section 35(2AB) claim on that leg collapses even if the underlying eligibility test is met.
Ind AS 21 governs the forex treatment on foreign CRO payables. The invoice is recorded at the transaction-date spot rate; unsettled payables are retranslated at the reporting-date closing rate with the exchange difference recognised in P&L. The Section 35(2AB) claim base is the transaction-date rupee value of the CRO expenditure — not the reporting-date or settlement-date value — so the forex movement on the payable is a separate P&L line and does not enter the Form 3CL quantum.
A worked example — an illustrative innovation centre commissioning three CROs
Illustrative — the following figures represent the operating pattern of a Tier-1 Indian innovator running a DSIR-approved R&D innovation centre at the scale that Sun Pharma Innovation Centre, Zydus Cadila Research or Dr Reddy’s Bollaram operate. Public disclosures do not reveal per-CRO per-invoice Section 35(2AB) eligibility carve-outs at this granularity; cross-verify against your own Form 3CL working papers and CRO contract file before action.
The innovator’s FY 2026-27 outsourced CRO expenditure at the Vadodara DSIR-approved facility reconciles as follows, converted to Rs crore:
| Reconciliation line | CRO | Nature of work | Value (Rs crore) | Section 35(2AB) eligibility | TDS provision |
|---|---|---|---|---|---|
| Phase 2 dose-finding — diabetes molecule | India-domiciled specialised CRO | Clinical trial execution at DSIR-linked protocol | 42.0 | Eligible | Section 194J code 1005 at 10 percent |
| Phase 3 registration-study consulting — cardiovascular molecule | India arm of global CRO | Regulatory strategy + market-access research + trial-design consulting | 18.0 | Non-eligible (Section 37) | Section 194J code 1005 at 10 percent on India-entity invoicing; Section 195 at DTAA rate on foreign-parent invoicing |
| Bioanalytical standing work | India-domiciled bioequivalence CRO | Bioanalytical validation, PK sample analysis at DSIR-linked programme | 6.0 | Eligible | Section 194J code 1005 at 10 percent |
| Aggregate outsourced CRO expenditure | 66.0 | 48.0 eligible + 18.0 Section 37 |
Form 3CL year-end quantum certification for the FY 2026-27 outsourced CRO line reads Rs 48 crore of Section 35(2AB) eligible outsourced expenditure — the Rs 42 crore Phase 2 diabetes-molecule clinical trial at the India-domiciled CRO (contract linked to the Vadodara facility Form 3CM approval; protocol filed at DSIR under the facility umbrella; invoice-level supporting evidence complete) plus the Rs 6 crore bioanalytical standing work at the specialised bioequivalence CRO. The Rs 18 crore Phase 3 CRO commission on the cardiovascular molecule fails the eligibility test because the scope-of-work is dominated by regulatory strategy consulting, competitor landscape review and market-access research — none of which fall within DSIR/Sec35(2AB)/1/2021 as scientific research, even where the underlying molecule is an internally-discovered NCE. The Rs 18 crore drops to Section 37 treatment and is reported in the general P&L schedule of ITR-6 rather than the Form 3CLA Section 35(2AB) schedule.
The TDS reconciliation runs invoice-by-invoice. All three CROs are India-domiciled entities invoicing in rupees against a PAN — the fact that the India arm of the global CRO sits under a foreign parent does not change the Section 194J treatment where the invoicing entity is the India-domiciled subsidiary. Section 194J TDS at 10 percent applies on all three under payment code 1005, deducted at credit or payment (whichever is earlier), deposited by the seventh of the following month, and reported quarterly in Form 26Q. Where any leg of a CRO’s scope-of-work is invoiced directly from the foreign parent (an ancillary regulatory review by the group headquarters, for example), that specific invoice falls under Section 195 at the applicable DTAA rate and requires a Form 27Q filing. Foreign-parent invoicing with an unsettled March-year-end payable engages the Ind AS 21 retranslation surface — the transaction-date rupee value feeds the Form 3CL quantum; the reporting-date and settlement-date retranslations flow only to the P&L forex-movement line.
Common reconciliation breakages
Five breakages recur across Indian innovator pharma companies running the Section 35(2AB) outsourced CRO expenditure claim, and each maps to a specific control failure that a DSIR-empanelled CA qualification note or a subsequent Section 148 reopening will surface.
-
CRO fee treated as a monolithic Section 35(2AB) claim without a scope-of-work carve-out. The most common failure is booking the aggregate CRO fee to the R&D expenditure ledger with a single eligibility flag, without carving out the regulatory strategy consulting, market-access research and testing-outside-facility portions of the same CRO umbrella. Reconciliation discipline: the CRO contract register carries the eligibility flag per scope-of-work line item, not per contract; the invoice-level flag drives the ledger posting split between the R&D expenditure ledger (eligible) and the general business expenditure ledger (Section 37).
-
Clinical trial protocol not filed at DSIR under the facility umbrella. DSIR/Sec35(2AB)/1/2021 requires the CRO-executed protocol to be filed at DSIR under the approved facility’s programme. Teams that file the initial Form 3CM approval and the year-end Form 3CL but not the interim protocol acknowledgements as trials commence fail the second leg of the eligibility test at any scrutiny even if the contract linkage and Form 3CL certification are intact. Reconciliation discipline: the CRO contract register carries a DSIR-protocol-acknowledgement column populated as each protocol is filed; a missing acknowledgement blocks the invoice-level eligibility flag.
-
Foreign CRO under Section 194J instead of Section 195, or without any TDS deduction. The invoicing entity’s country of tax residence — not the operating country of the underlying work — governs the TDS provision. Confusing the two, or omitting TDS entirely on the ground that “the work was done in India”, triggers Section 40(a)(i) disallowance on the foreign CRO leg. The full expenditure is disallowed in the year of payment; the Section 35(2AB) claim on that leg collapses; the innovator carries an assessment-year exposure that surfaces at scrutiny or at a subsequent Section 148 reopening.
-
Ind AS 21 forex retranslation missed on foreign CRO payable, distorting the R&D expenditure feed. Where a foreign CRO invoice raised in USD or EUR remains unsettled at the reporting date, the payable must be retranslated at the closing spot rate with the exchange difference recognised in P&L. Finance teams that hold the CRO payable at the transaction-date rupee value at reporting date miss the forex movement, and worse, may conflate it with the R&D expenditure line and distort the Form 3CL quantum. Reconciliation discipline: expenditure ledger and payable ledger are separate; the transaction-date rupee value flows to the R&D ledger and feeds Form 3CL; the retranslation flows only to the payable ledger and to the P&L forex-movement line.
-
CRO invoice recognised in the wrong tax period, distorting the Form 3CL quantum. A CRO milestone invoice raised in March but for work performed across March and April straddles the year-end cutover. On the accrual basis, the March-work portion is recognised in the closing FY and the April-work portion in the opening FY. Recognising the full invoice in the year of receipt distorts the Form 3CL quantum for either FY. Reconciliation discipline: CRO milestone invoices are recognised on an accrual basis with a work-completion cutoff at the reporting date, with the unaccrued portion held as a prepayment for the opening FY.
How a reconciliation platform handles this
A purpose-built pharma reconciliation platform ingests the innovator’s CRO contract register, the CRO invoice register with per-invoice scope-of-work detail, the TDS challan register, and the CRO payable ledger with the forex retranslation trail — and produces a per-CRO per-invoice Section 35(2AB) eligibility flag, a Form 3CL supporting-evidence pack for the DSIR-empanelled Chartered Accountant, a TDS challan reconciliation matched by CIN to each CRO invoice, and a Section 40(a)(i) exposure flag for any foreign CRO leg where the TDS chain is incomplete. The platform holds the transaction-date rupee value of foreign CRO invoices separately from the reporting-date and settlement-date retranslation trail so the Form 3CL quantum feed is not conflated with the Ind AS 21 forex movement. Match rate improvement of 51 to 88 percent on the CRO invoice to TDS challan reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling on the R&D pipeline data (which is commercially sensitive), is what makes the platform an infrastructure investment for a Tier-1 Indian innovator running an active DSIR-approved facility with outsourced CRO commitments running into hundreds of crore annually.
Cross-cluster bridges and where to read next
The Section 35(2AB) outsourced CRO expenditure carve-out documented here sits alongside three Pharma companions in Theme 6 (DSIR / Section 35(2AB) / R&D accounting). The Section 35(2AB) weighted deduction pharma R&D reconciliation guide is the Theme 6 cornerstone — the full-scope walkthrough of the claim across salaries, consumables, in-house clinical trial costs, patent filing and prosecution, publications, and DSIR-listed equipment. The DSIR Form 3CL and 3CLA R&D approval reconciliation walkthrough covers the year-end certification workflow with the DSIR-empanelled CA. The Ind AS 38 R&D capitalisation versus Section 35(2AB) treatment walkthrough covers the book-tax gap between Ind AS 38 development-phase capitalisation and the Section 35(2AB) revenue-expensed treatment, and the resulting deferred-tax asset or liability under Ind AS 12.
The TDS overlay on CRO payments — Section 194J code 1005 for India-domiciled CROs, Section 195 for foreign CROs — sits within the broader Terra Insight TDS payment-code coverage; the TDS payment code and Section 393 SL-8 purchase-of-goods reference covers the standing payment-code schedule, and the Section 393 payment code finder is the operating lookup surface for mapping a payment nature to the correct code.
The methodology framework for building the CRO contract register, the eligibility flag per invoice and the Form 3CL supporting-evidence chain sits in Terra Insight’s own reconciliation failure mode analysis design-layer pillar and the reconciliation playbook for monthly close operations pillar. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India with the specialised TDS reconciliation software surface for the Section 194J and Section 195 CRO-payment TDS reconciliation workflow.
The five FAQs below address the operational questions Indian innovator-pharma R&D controllers, DSIR-empanelled Chartered Accountants and clinical operations leads ask most often when building the standing Section 35(2AB) outsourced CRO expenditure claim.
Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
- ▸ Section 35(2AB), Income-tax Act 2025 (successor to Section 35(2AB), Income-tax Act 1961) — Weighted deduction of 100 percent of revenue expenditure and capital expenditure (other than expenditure on land and buildings) incurred on scientific research at an in-house research and development facility approved by the prescribed authority. The weighted rate was 200 percent up to assessment year 2017-18, reduced to 150 percent from assessment year 2018-19 to assessment year 2020-21, and stands at 100 percent from assessment year 2021-22 onwards. The prescribed authority is the Department of Scientific and Industrial Research under the Ministry of Science and Technology. The deduction is available only in respect of expenditure incurred at the approved facility, subject to year-end quantum certification by a DSIR-empanelled Chartered Accountant in Form 3CL and disclosure in the Return of Income in Form 3CLA.
- ▸ DSIR guidelines DSIR/Sec35(2AB)/1/2021 for approval of in-house R&D facility and eligibility of expenditure — The guidelines set out the categories of eligible R&D expenditure for the Section 35(2AB) weighted deduction: scientific research staff salaries; consumables (chemicals, biological materials, cell lines, reference standards); clinical trial internal costs (in-house preclinical, bioanalytical work at the approved facility); patent filing and prosecution costs (Indian and foreign); cost of scientific publications; and equipment and other items on the DSIR-approved list. Land and buildings are excluded from the weighted deduction scope (though a separate deduction is available for revenue expenditure). Civil engineering, market research, regulatory strategy consulting, and testing outside the DSIR-approved facility are excluded. Outsourced clinical trial fees paid to a Contract Research Organisation (CRO) are eligible only where the CRO operates under a contract linked to the DSIR-approved facility, the clinical trial protocol is filed at DSIR under the facility umbrella, and the expenditure is certified in Form 3CL by the DSIR-empanelled Chartered Accountant.
- ▸ Form 3CM, Form 3CL and Form 3CLA — R&D facility approval and quantum certification — Form 3CM is the DSIR in-principle approval of the in-house R&D facility, issued initially on a three-year renewal cycle and thereafter renewed at the end of each cycle subject to continued eligibility. Form 3CL is the year-end quantum certification by a DSIR-empanelled Chartered Accountant of the eligible R&D expenditure incurred at the approved facility during the relevant financial year; it must be filed with the income-tax return. Form 3CLA is the schedule to the Return of Income (typically ITR-6 for companies) where the Section 35(2AB) claim is disclosed with the Form 3CL quantum, the Form 3CM approval reference, and the split between eligible revenue expenditure and eligible capital expenditure.
- ▸ Section 194J and Section 195, Income-tax Act 2025 — TDS on professional fees and payments to non-residents — Section 194J applies to payments to residents in respect of fees for professional services (including services rendered by domestic Contract Research Organisations and clinical research consultants) at 10 percent, reported under the applicable payment code (1005 in the standing payment-code schedule for fees for professional services). Section 195 applies to any interest or other sum chargeable under the Act payable to a non-resident — including a foreign CRO or a foreign parent of an India-domiciled CRO where the invoice is raised on the foreign entity — at the rate specified in the Finance Act or the applicable Double Taxation Avoidance Agreement (DTAA), whichever is more beneficial to the assessee. Failure to deduct or pay TDS on a payment to a non-resident triggers disallowance of the expenditure under Section 40(a)(i) — the full disallowance of the foreign CRO fee for the year of the payment.
- ▸ Section 37, Income-tax Act 2025 — General deduction for business expenditure — Any expenditure (not being expenditure of the nature described in sections 30 to 36 and not being capital expenditure or personal expenditure) laid out or expended wholly and exclusively for the purposes of the business or profession is allowed as a deduction in computing the income chargeable under the head 'Profits and gains of business or profession'. Regulatory strategy consulting fees, market-access research, and other business-support expenditure that fails the Section 35(2AB) scientific-research eligibility test remains deductible under Section 37 subject to the wholly-and-exclusively test — but does not carry the Section 35(2AB) weighted-deduction benefit and must be reported in a distinct return-of-income schedule.
- ▸ Ind AS 21 — The Effects of Changes in Foreign Exchange Rates — A foreign currency transaction is recorded on initial recognition at the spot exchange rate between the functional currency and the foreign currency at the date of the transaction. At each subsequent reporting date, foreign currency monetary items (payables, creditors) are retranslated at the closing rate; the resulting exchange difference is recognised in profit or loss in the period in which it arises. For a pharma innovator paying a foreign CRO — invoice raised in USD, milestone payments spread across two or more reporting dates — the retranslation surface produces a period-end forex gain or loss that must reconcile against the rupee-equivalent expenditure booked in the profit-and-loss account and against the rupee-equivalent Section 35(2AB) or Section 37 line in the tax return.